Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oklahoma
Clinical trial register · United States · industry-sponsored

Clinical Trials in Oklahoma, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4438 Illinois 2485 Georgia 2364 Arizona 2242
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca5 Pfizer4 Sanofi4 Novartis Pharmaceuticals4 Takeda4
State
California5299 Florida4438 Illinois2485 Georgia2364 Arizona2242
All 51 states
Target enrolment
to

Trials with a site in Oklahoma

176 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Novo Nordisk A/S
Phase 3
84
Iowa, Louisiana, Minnesota, Missouri, North Carolina, Oklahoma, Pennsylvania, Texas
2026-10-09
Recruiting
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Indiana, Kentucky, Oklahoma, Pennsylvania
2026-09-23
Recruiting
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Recruiting
WiQo S.p.A.
Not applicable
30
Kansas, Oklahoma
2026-09-21
Recruiting
BioLab Holdings
Not applicable
160
Oklahoma
2026-09-18
Not yet open
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
285
California, Florida, Massachusetts, Oklahoma, Texas, Virginia
2026-09-14
Not yet open
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
DrugSI-B036
SystImmune Inc.
Phase 1
424
Connecticut, Florida, Oklahoma, Tennessee, Texas
2026-09
Not yet open
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-09
Recruiting
Pfizer
Phase 3
1,375
Arizona, California, Georgia, Indiana, Michigan, Oklahoma, Pennsylvania, Tennessee
2026-08-24
Recruiting
Novartis Pharmaceuticals
Phase 2
344
Florida, Illinois, Oklahoma, Pennsylvania, Texas
2026-08-24
Recruiting
Pedal Pump Clinical Trial on Edema V2
NCT07809516Lower Extremity Edema, Lower Extremity Edema Chronic, CHF - Congestive Heart Failure, CHF Exacerbation
Hillcrest
Not applicable
30
Oklahoma
2026-08-21
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma
2026-08-20
Recruiting
Pedal Pump Clinical Trial on Edema V1
NCT07760363Lower Extremity Edema, Congestive Heart Failure(CHF), Chronic Venous Insufficiency (CVI), Kidney Disease
David McVay
Not applicable
60
Oklahoma
2026-08-06
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-06
Not yet open
Oneness Biotech Co., Ltd.
Not applicable
100
Florida, Louisiana, New York, Ohio, Oklahoma, Pennsylvania
2026-08
Not yet open
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New York, North Carolina, Oklahoma
2026-07-16
Recruiting
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
NCT06552637Heart Failure With Reduced Ejection Fraction
VisCardia Inc.
Not applicable
270
Indiana, Oklahoma, Pennsylvania, Texas
2026-07-08
Recruiting
Happitech BV
Observational
554
Arkansas, Colorado, Louisiana, Oklahoma
2026-06-30
Recruiting
xDot Access Management System Early Feasibility Study
NCT07464353Vascular Closure Devices
xDot Medical, Inc
Not applicable
30
Illinois, Minnesota, Oklahoma, South Dakota, Wisconsin
2026-06-16
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
NCT07811726Wet Age Related Macular Degeneration
NexThera Co., Ltd.
Phase 2
66
Florida, Oklahoma, Pennsylvania
2026-06-11
Recruiting
NORM-HF Pivotal Study
NCT07574593Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
800
California, Florida, New York, Ohio, Oklahoma, Pennsylvania, South Dakota
2026-05-29
Recruiting
Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
NCT07627971GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
Skylark Bio Inc.
Phase 1/2
10
Maryland, Massachusetts, Oklahoma, Pennsylvania
2026-05-28
Recruiting
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
By invitation
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Recruiting
GlaxoSmithKline
Phase 3
456
Arkansas, California, Colorado, Florida, Louisiana, Oklahoma, Pennsylvania, South Dakota
2026-03-13
Active, closed
Sanofi
Phase 3
59
California, Oklahoma
2026-03-12
Recruiting
Bristol-Myers Squibb
Phase 4
35
Connecticut, New York, Oklahoma, Tennessee
2026-02-24
Recruiting
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
Generate Biomedicines
Phase 3
786
California, Florida, Kansas, Massachusetts, Michigan, New York, Ohio, Oklahoma
2026-01-20
Recruiting
Sun Pharmaceutical Industries Limited
Phase 2
285
Arkansas, Florida, Kansas, Oklahoma
2026-01-20
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 3
126
California, Florida, Hawaii, Kansas, New York, Ohio, Oklahoma, Texas
2025-11-14
Recruiting
UCB Biopharma SRL
Phase 3
320
Alabama, California, Florida, Michigan, Ohio, Oklahoma
2025-11-14
Recruiting
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, Oklahoma
2025-10-30
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Active, closed
Eli Lilly and Company
Phase 2
100
Arizona, California, Florida, Iowa, Missouri, North Carolina, Oklahoma, South Carolina
2025-10-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
300
California, Connecticut, Florida, Georgia, Maryland, New Jersey, Oklahoma, Pennsylvania
2025-10-09
Recruiting
Oystershell NV
Not applicable
86
Oklahoma
2025-10-02
Recruiting
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
NCT06813820Left Ventricle Remodeling, Left Ventricle Dilated, CHF
BioVentrix
Not applicable
135
Arizona, Florida, Illinois, Missouri, Oklahoma, Pennsylvania
2025-09-29
Active, closed
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU
NCT07223281Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Legacy Medical Consultants
Observational
2,400
Colorado, Michigan, Oklahoma, West Virginia
2025-09-25
Active, closed
Aleniglipron Phase 2 Body Composition Study
NCT07169942Obesity, Overweight, or Chronic Weight Management
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
71
Arizona, Illinois, Minnesota, Missouri, New York, North Carolina, Oklahoma, South Carolina
2025-08-15
Recruiting
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
NCT07209475Diabetic Foot Ulcer (DFU), Amnio-Maxx
Royal Biologics
Phase 4
248
California, Florida, Georgia, Nebraska, New York, Oklahoma, Texas
2025-08-14
Recruiting
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Active, closed
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
Glaukos Corporation
Phase 2
110
Colorado, Oklahoma, Texas
2025-06-12
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Active, closed
Gilead Sciences
Phase 1
65
Alabama, California, Florida, Illinois, Louisiana, Oklahoma, Pennsylvania, Texas
2025-05-14
By invitation
Sanofi
Phase 2
71
California, Idaho, Oklahoma, Texas, Virginia
2025-05-12
Not yet open
Cell>Point LLC
Phase 2
60
Oklahoma
2025-05-10
Recruiting
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
Elephas
Observational
2,000
Arkansas, Maryland, Missouri, Oklahoma, Texas
2025-04-14
Active, closed
Apogee Therapeutics, Inc.
Phase 1
31
California, Illinois, Missouri, Oklahoma, Pennsylvania
2025-03-27
By invitation
Karma Ambispective Study
NCT07207187Subjects Treated With Karma Fixation System as Part of Their Spine Surgery
Spinal Elements
Observational
100
Arizona, Florida, Louisiana, Oklahoma
2025-03-06
Recruiting
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NCT06590961Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.
Phase 1
94
Michigan, Oklahoma, Texas
2025-02-20
Recruiting
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1/2
280
California, North Carolina, Oklahoma, Texas
2025-02-17
Recruiting
Everest Detection, Inc.
Observational
350
Oklahoma
2025-02-17
Active, closed
Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant
NCT06699797Sensori-Neural Deafness, Sensorineural Hearing Loss, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Bilateral
Envoy Medical Corporation
Not applicable
56
Arizona, California, Florida, Minnesota, Ohio, Oklahoma, South Carolina
2025-02-06
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
DrugsKQB198·Cetuximab
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
PerQdisc Traditional Feasibility Trial.
NCT06860867Discogenic Low Back Pain
Spinal Stabilization Technologies
Not applicable
5
Arizona, Idaho, Indiana, Louisiana, Oklahoma
2025-01-10
By invitation
The ION Facet Screw System Ambispective Evaluation
NCT06720948Intra-facet ION 3D Facet Screw System
SurGenTec LLC
Observational
50
Indiana, Oklahoma, Texas
2025-01-01
Recruiting
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma, Tennessee
2024-12-16
Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Fresenius Kabi
Observational
40
California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington
2024-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Recruiting
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Connecticut, Ohio, Oklahoma, Texas, Virginia
2024-10-30
Recruiting
Iovance Biotherapeutics, Inc.
Phase 2
60
Arizona, California, Florida, Georgia, Kentucky, Michigan, New York, Oklahoma
2024-10-29
Active, closed
Amgen
Phase 1
21
California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma
2024-10-16
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Active, closed
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Active, closed
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
NCT05839730Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
105
Florida, Illinois, Kansas, North Carolina, Oklahoma, Texas, Vermont
2024-09-11
Recruiting
GlaxoSmithKline
Phase 1
142
Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas
2024-09-02
Recruiting
Octapharma
Phase 3
120
California, Florida, Massachusetts, North Carolina, Ohio, Oklahoma, Texas
2024-08-21
Recruiting
Noveome Biotherapeutics, formerly Stemnion
Phase 1/2
36
Arkansas, Connecticut, Florida, Illinois, Oklahoma, Pennsylvania
2024-08-19
Recruiting
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
NCT06319963HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Theravectys S.A.
Phase 1/2
72
Florida, Oklahoma
2024-08-08
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
705
California, Florida, Georgia, Michigan, New Jersey, New York, Ohio, Oklahoma
2024-08-05
Active, closed
Palatin Technologies, Inc
Phase 2
108
Florida, Oklahoma, South Carolina, Tennessee
2024-08-05
Recruiting
Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs
NCT06449638Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
StimLabs
Not applicable
272
Nebraska, Oklahoma, Pennsylvania
2024-07-16
Recruiting
Surgenex
Not applicable
180
California, Oklahoma
2024-06-23
Recruiting
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Recruiting
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Recruiting
Sanofi
Phase 3
18
California, Florida, Minnesota, Missouri, North Dakota, Oklahoma, Texas
2024-05-15
Recruiting
Biohaven Therapeutics Ltd.
Phase 1/2
500
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New York, Oklahoma
2024-04-22
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
Recruiting
Exelixis
Phase 1
429
California, Florida, Minnesota, Missouri, New Jersey, New York, Ohio, Oklahoma
2024-04-03
Recruiting
Pacira Pharmaceuticals, Inc
Phase 1
48
Indiana, Missouri, North Carolina, Oklahoma, Texas
2024-03-29
Active, closed
Lipogems International spa
Phase 3
173
Arizona, California, Florida, Georgia, Louisiana, Maryland, Minnesota, Oklahoma
2024-03-15
Active, closed
A Study in Patients With Mixed Dyslipidemia
NCT06497127Mixed Dyslipidemia
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
145
Alabama, Florida, Georgia, Illinois, Kansas, New York, Oklahoma, Texas
2024-02-28
Active, closed
VIA Disc NP Registry 3.0
NCT06345690Discogenic Pain, Back Pain, Back Pain, Low
VIVEX Biologics, Inc.
Observational
500
Arkansas, Colorado, Florida, Georgia, Indiana, Louisiana, North Carolina, Oklahoma
2024-02-27
Recruiting
Laplace Interventional, Inc
Not applicable
65
Arizona, California, Georgia, Minnesota, New Hampshire, New York, Ohio, Oklahoma
2024-02-19
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
40
Alabama, Arizona, California, Florida, North Carolina, Oklahoma, Pennsylvania, South Carolina
2024-02-08
Recruiting
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
Aadi Bioscience, Inc.
Phase 2
29
Arkansas, Florida, Nevada, New York, North Carolina, Oklahoma, Rhode Island, Texas
2023-12-28
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma
2023-11-14
Recruiting
A2A Pharmaceuticals Inc.
Phase 1
86
Michigan, Oklahoma, South Carolina, Texas, Virginia
2023-11-02
Recruiting
aTyr Pharma, Inc.
Phase 2
25
California, Florida, Illinois, Louisiana, New York, Ohio, Oklahoma, South Carolina
2023-10-26
Recruiting
Exactech
Observational
2,946
Oklahoma
2023-10-13
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Recruiting
Travoprost Intraocular Implant + iStent Infinite
NCT06066645Glaucoma, Open-Angle
Glaukos Corporation
Phase 4
150
Oklahoma
2023-09-14
Active, closed
Cantex Pharmaceuticals
Phase 2
30
Colorado, Florida, Michigan, Missouri, New York, Oklahoma, Utah, Washington
2023-09-12
Recruiting
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
DrugsLurbinectedin·Topotecan·Irinotecan·Etoposide
Phanes Therapeutics
Phase 1/2
203
California, Colorado, Connecticut, Maryland, Massachusetts, Missouri, North Carolina, Oklahoma
2023-09-05
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Active, closed
Abbott Ventricular Tachycardia PAS
NCT05839873Ventricular Tachycardia
Abbott Medical Devices
Observational
62
Florida, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Oklahoma, South Carolina
2023-07-24
Active, closed
Novartis Pharmaceuticals
Phase 3
100
California, Florida, Idaho, Illinois, Kentucky, Ohio, Oklahoma, Pennsylvania
2023-07-11
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
USWM CT, LLC
Phase 2
66
Arizona, California, Georgia, Michigan, New Jersey, Ohio, Oklahoma, South Dakota
2023-06-26
Active, closed
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction
NCT05870488Sacroiliac Joint Dysfunction, Sacroiliac; Fusion, Sacroiliac Disorder, Sacroiliac Joint Pain
SI-BONE, Inc.
Phase 4
110
California, Indiana, Kansas, Kentucky, Maryland, Missouri, Nevada, Oklahoma
2023-05-23
Recruiting
Pfizer
Phase 3
318
Arizona, California, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma
2023-05-20
Active, closed
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
NCT05561374High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
Oblato, Inc.
Phase 1
16
California, Kentucky, North Carolina, Oklahoma
2023-04-17
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Active, closed
Edwards Lifesciences
Not applicable
100
California, Illinois, Kansas, Minnesota, New York, Ohio, Oklahoma, Oregon
2023-04-01
Active, closed
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
All4Cure
Observational
200
Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington
2023-03-01
Active, closed
Investigation of DEXA-C Anterior Cervical Interbody System
NCT05883436Degenerative Disc Disease
Aurora Spine and Pain
Not applicable
71
California, Kentucky, Louisiana, Oklahoma
2023-02-22
Recruiting
Imunon
Phase 1/2
30
Maryland, New York, Oklahoma, Texas
2023-02-10
Active, closed
Kaneka Medical America LLC
Not applicable
164
Michigan, New York, Ohio, Oklahoma
2022-12-13
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
DrugIP-001
Immunophotonics, Inc.
Phase 1/2
42
Florida, Kentucky, Oklahoma
2022-11-29
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Active, closed
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
IGC Pharma, LLC
Phase 2
164
Florida, Louisiana, Maryland, Missouri, New York, Oklahoma, Rhode Island, Texas
2022-10-11
Active, closed
Jazz Pharmaceuticals
Phase 1
98
California, Colorado, Florida, Illinois, New York, Oklahoma, Pennsylvania, Tennessee
2022-10-10
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Alabama, Connecticut, Florida, Kansas, Kentucky, Missouri, New York, Oklahoma
2022-09-27
Recruiting
AngelMed Guardian® System PMA Post Approval Study
NCT05412927Acute Coronary Syndrome
Angel Medical Systems
Observational
500
Arizona, California, Florida, Georgia, Louisiana, Michigan, Oklahoma, Texas
2022-09-07
Recruiting
Takeda
Phase 3
440
Arkansas, California, Colorado, Florida, New Jersey, North Carolina, Ohio, Oklahoma
2022-08-24
Recruiting
Phanes Therapeutics
Phase 1/2
40
North Carolina, Oklahoma, Tennessee, Texas, Virginia
2022-08-11
Active, closed
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
NCT05335993Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
DrugsOregovomab·Niraparib
CanariaBio Inc.
Phase 2
10
North Carolina, Oklahoma, Virginia
2022-07-25
Recruiting
Tempus AI
Observational
200
California, Colorado, Illinois, Maryland, New Jersey, North Carolina, Ohio, Oklahoma
2022-07-13
Active, closed
Nevro Corp
Not applicable
497
Alaska, Michigan, Ohio, Oklahoma, Oregon, Pennsylvania, Virginia
2022-07-05
Recruiting
BioRestorative Therapies
Phase 2
99
Alabama, California, Colorado, Florida, New York, North Carolina, Ohio, Oklahoma
2022-06-30
Recruiting
Tempus AI
Observational
300
Arkansas, California, Maryland, Missouri, Nebraska, North Carolina, Ohio, Oklahoma
2022-06-21
Active, closed
Hoffmann-La Roche
Phase 4
136
California, Florida, Oklahoma
2022-06-20
Active, closed
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Active, closed
GlaxoSmithKline
Phase 1
152
California, North Carolina, Oklahoma, Pennsylvania, Texas, Utah
2022-03-22
Active, closed
LIFE-BTK PK Sub-study
NCT05208905Critical Limb Ischemia (CLI)
Abbott Medical Devices
Not applicable
9
Florida, Massachusetts, Oklahoma
2022-02-10
Active, closed
Curevo Inc
Phase 2
1,516
Arizona, Florida, Illinois, Kansas, Kentucky, Nevada, Oklahoma, Tennessee
2022-02-02
Active, closed
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
DT MedTech, LLC
Not applicable
94
Arkansas, California, Florida, Indiana, Maryland, New Mexico, North Carolina, Oklahoma
2022-02-01
Active, closed
argenx
Phase 3
173
Arkansas, District of Columbia, Indiana, Iowa, Oklahoma
2021-11-17
Active, closed
Sanofi
Phase 2
109
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Tennessee
2021-11-10
Active, closed
Hoffmann-La Roche
Phase 2
176
California, Missouri, North Carolina, Ohio, Oklahoma, Texas, Virginia, Washington
2021-10-07
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
California, Colorado, Illinois, North Carolina, Oklahoma, Texas, Virginia, Washington
2021-09-29
By invitation
AbbVie
Phase 3
124
California, Florida, Georgia, Oklahoma, Pennsylvania
2021-08-13
Active, closed
Takeda
Phase 3
77
Georgia, New York, North Carolina, Ohio, Oklahoma
2021-04-14
Active, closed
Kedrion S.p.A.
Phase 3
30
California, Colorado, Florida, Louisiana, North Carolina, Ohio, Oklahoma
2021-03-31
Active, closed
Daiichi Sankyo
Phase 1
179
Arizona, Colorado, Florida, Oklahoma, Tennessee
2020-12-22
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
AbbVie
Phase 1
21
California, New Hampshire, New York, Ohio, Oklahoma, Oregon, Texas, Washington
2020-11-11
Active, closed
Razor Genomics
Not applicable
420
California, Florida, Kentucky, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania
2020-09-11
Active, closed
Genentech, Inc.
Phase 1
498
California, Connecticut, Florida, Massachusetts, New York, Oklahoma, Pennsylvania
2020-07-29
Recruiting
BioInvent International AB
Phase 1/2
197
California, Colorado, Minnesota, Oklahoma, Texas
2020-06-29
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
California, Florida, Michigan, Oklahoma, Oregon, Texas, Virginia
2020-02-28
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
California, Colorado, Florida, Michigan, Nevada, New York, Oklahoma, Pennsylvania
2019-11-07
Active, closed
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
USWM CT, LLC
Phase 1
120
Florida, Massachusetts, Missouri, New York, North Carolina, Oklahoma, Tennessee, Texas
2019-08-20
Active, closed
Dentsply Sirona Implants and Consumables
Not applicable
160
Illinois, Oklahoma
2019-07-30
Active, closed
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
NCT03949283Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Cordgenics, LLC
Phase 3
150
California, Florida, Louisiana, Ohio, Oklahoma, Pennsylvania, West Virginia
2019-07-26
Active, closed
Novo Nordisk A/S
Phase 2
62
Alabama, California, Idaho, Minnesota, New Jersey, New York, Ohio, Oklahoma
2019-07-04
Recruiting
Amgen
Phase 3
56
California, Colorado, Missouri, New York, Ohio, Oklahoma, Pennsylvania, Texas
2019-04-29
Recruiting
Allarity Therapeutics
Phase 2
40
Oklahoma, Washington
2019-04-15
Recruiting
Allarity Therapeutics
Observational
60
Florida, Georgia, New Mexico, New York, Oklahoma, Texas, Washington
2019-04-11
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Maryland, Massachusetts, New York, Oklahoma, South Carolina
2019-03-07
Active, closed
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
NCT03393884Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsIMNN-001·Paclitaxel·Carboplatin
Imunon
Phase 1/2
130
Alabama, California, Florida, Massachusetts, Missouri, New Jersey, New York, Oklahoma
2018-09-05
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Alabama, Massachusetts, Minnesota, New York, Ohio, Oklahoma, Tennessee, Texas
2018-05-21
Active, closed
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
NCT03319628Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Mersana Therapeutics
Phase 1/2
523
Oklahoma
2017-12-12
By invitation
Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty
NCT06203756Arthroplasties, Knee Replacement, Revision Arthroplasty
Corin
Not applicable
713
Arizona, Connecticut, Michigan, New York, Oklahoma, Wisconsin
2017-11-09
Recruiting
Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867Hepatocellular Carcinoma, Gastric Cancer
DrugOpdivo
Teclison Ltd.
Phase 2
54
California, Oklahoma, Wisconsin
2017-07-01
Recruiting
Physica System Total Knee Replacement Registry Study
NCT03048201Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee
Limacorporate S.p.a
Not applicable
800
California, Florida, Illinois, New York, Oklahoma
2017-03-24
Active, closed
Supernus Pharmaceuticals, Inc.
Phase 3
1,400
Arkansas, California, Colorado, Florida, Oklahoma, Tennessee, Texas, Utah
2016-02-02
Active, closed
Triathlon Tritanium Cone Augments Outcomes Study
NCT02521103Arthroplasty, Replacement, Knee
Stryker Orthopaedics
Not applicable
254
Florida, Illinois, Kentucky, Michigan, Missouri, New Jersey, Oklahoma, Washington
2015-08
Rows per page Showing 1–176 of 176
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/oklahoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 176 of those studies with a site in Oklahoma.

How many clinical trials are recruiting in Oklahoma?

100 of the 176 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 7 have not yet opened recruitment, 63 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Oklahoma), 176 studies
PhaseStudiesRecruitingShare
Phase 2342019.3%
Phase 1321418.2%
Phase 3321918.2%
Not applicable301717%
Phase 1/2251614.2%
Observational181110.2%
Phase 4532.8%

Most active sponsors

Lead sponsors with the most studies (Oklahoma)
Lead sponsorStudiesRecruiting
AstraZeneca52
GlaxoSmithKline43
Novartis Pharmaceuticals43
Pfizer44
Sanofi41
Takeda43
AbbVie31
Amgen31
Merck Sharp & Dohme LLC33
Abbott Medical Devices20
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.